Pfizer's Failed OvertheCounter Lipitor Trial Highlights Limits of Patient...
Clinical Informatics News Pfizer has abandoned an effort to get its blockbuster statin Lipitor cleared for overthecounter sales after a trial demonstrated that patients would not follow up with...
View ArticleEzetimibe Added to Statin Furthers Plaque Regression by IVUS
The findings "could lead to an early reevaluation of the new ACCAHA lipidmanagement guidelines that endorse statins as the only recommended drugs for treating cholesterolrelated CV...
View ArticleAmgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And...
THOUSAND OAKS Calif. July 30 2015 PRNewswire &160;Amgen NASDAQAMGN today announced financial results for the second quarter of 2015. Key results includeTotal revenues increased 4 percent versus the...
View ArticleAmarin Announces Upcoming Presentations of Two Eicosapentaenoic Acid EPA...
BEDMINSTER NJ and DUBLIN IRELANDMarketwired July 31 2015 Amarin Corporation plc NASDAQ AMRN today announced the presentation of findings from two studies a retrospective study in which patients were...
View ArticleDRAFT v10 Esperion Therapeutics ESPR Investor Day
On Thursday July 30 2015 Esperion Therapeutics ESPR held a 3.5 hour Investor Day presentation that provided a drug profile of ETC1002 as well managements proposed regulatory and commercialization path....
View ArticleCardioBreak Drug MixUp Warning No OTC Statin
MedPage Today Recent developments of interest in cardiovascular medicine
View ArticleFirst Amendment Decision a Win for Amarin and Physician Plaintiffs
BEDMINSTER NJ and DUBLIN IRELANDMarketwired August 07 2015 Amarin Corporation plc NASDAQ AMRN today announced a United States District Court has ruled that Amarin may promote to healthcare...
View ArticleDRAFT Esperion Therapeutics ESPR Q2 2015 Update
On August 6 2015 Esperion Therapeutics ESPR announced its results for Q2 2015 and held a conference call. You can also download the associated presentation. You can also obtain the pdf of the SEC Form...
View ArticleAIS Webinar to Offer Strategies to Prepare for PCSK9 Costs
In an Aug. 20 webinar two industry experts will discuss the potential upside and downside to the market entry of PCSK9 inhibitors and share strategies for reining in costs before they spiral out of...
View ArticleUsing NHS data on statin outcomes
The BMJ is right to call for the release of more clinical trial data on statins1 but perhaps it should also push to use the huge amount of data the NHS already collects.Nearly 70 million...
View ArticleCVS seeks clearer guidance on PCSK9s
With one PCSK9 inhibitor on the market and a second on the horizon CVS Health Corp. NYSECVS executives published a commentary in the Journal of the American Medical Association urging cardiologists to...
View ArticleWhy statins should be viewed as a doubleedged sword
Statins have significant cardiovascular benefits but also serious side effects. A new study finds that statin use impairs stem cell function which helps in slowing atherosclerosis but hinders other...
View ArticleGoodes Family Alzheimer's Drug Discovery Foundation Create New Prize For...
NEW YORK Aug. 12 2015 PRNewswireUSNewswire Thanks to the generosity of former WarnerLambert CEO and Chairman Melvin R. Goodes and his family the Alzheimer's Drug Discovery Foundation ADDF has...
View ArticleCatabasis Pharmaceuticals Announces Positive Topline Phase 1 Data for...
Safety Tolerability and Reductions in LDLC Observed Catabasis Pharmaceuticals Inc. NASDAQCATB a clinicalstage drug development company built on a pathway pharmacology technology platform today...
View ArticleEsperion Therapeutics Provides Update on the ETC1002 Development Program...
ANN ARBOR MIMarketwired August 17 2015 Esperion Therapeutics Inc. NASDAQ ESPR an emerging pharmaceutical company focused on developing and commercializing firstinclass oral lowdensity lipoprotein...
View ArticleStatin Use Linked to Lower Mortality in RA CMECE
MedPage Today Magnitude of association similar to that seen in general population
View ArticleFDA won't demand preapproval CVOT from Esperion
Esperion Therapeutics Inc. NASDAQESPR rose $7.99 11 to $83.50 in afterhours trading on Monday after it said FDA will not require a cardiovascular outcomes trial of ETC1002 prior to approval for the...
View Article